Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.5MCash on Hand
10.5mo Cash Runway
Follow INTS by emailGet an email when INTS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INTS, unsubscribe in one click. Privacy
📣 What INTS Says Is Next
by the end of 2027 · “In July 2026, the Company restarted patient enrollment and treatment in the INVINCIBLE-4 Study and is currently targeting complete enrollment by the end of 2027.”
Company press release, Nov 5, 2026 · SEC filing
second half of 2026 · “While early, we are pleased with the interest expressed in our science and clinical trials, and we expect to continue discussions in the second half of 2026.” Second Quarter 2026 Financial Results Research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same period in 2025.”
Company press release, Aug 11, 2026 · SEC filing
by the end of 2027 · “In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study and is currently targeting complete enrollment by the end of 2027.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: R&D expense of $2.4 million versus $1.6 million a year earlier, G&A of $1.2 million, and a net loss of $3.5 million. Cash and equivalents were $8.5 million at September 30, 2026. Enrollment resumed in the INVINCIBLE-3 and INVINCIBLE-4 trials. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 net loss of $3.0 million and cash of $9.5 million as of June 30, 2026. Restarted INVINCIBLE-4 patient treatment in July and resumed INVINCIBLE-3 enrollment at limited U.S. sites, with raised net proceeds of $1.6 million under its ATM in Q2. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 3 · Recruiting · A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not INTS's own candidates): Pazopanib, Trabectedin, Ipilimumab, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
INTS holds $8.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.4M/quarter from operations,
an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 10 months +30
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Jul 2024) +10
Going-concern doubt in the latest 10-Q +15As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.10-Q, Nov 2026
Share count 3,301,175 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full INTS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INTS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.